
Atopic Dermatitis NHP Model
Atopic Dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus, erythema, and epidermal barrier dysfunction. It is a multifactorial disease involving genetic susceptibility, immune dysregulation, and environmental triggers. The global prevalence of AD is increasing, affecting up to 20% of children and 10% of adults, with significant impacts on quality of life and economic burden. AD pathogenesis involves complex interactions among keratinocytes, immune cells, and the microbiome, making it a challenging yet essential target for therapeutic research.
Cause:
The pathogenesis of AD is multifaceted:
- Epidermal Barrier Dysfunction: Mutations in filaggrin (FLG) gene impair the barrier, increasing susceptibility to allergens and irritants.
- Immune Dysregulation: Overactivation of type 2 immune responses, driven by cytokines such as IL-4, IL-13, IL-31, and IL-33, leads to inflammation and pruritus.
- Microbiome Dysbiosis: Dominance of Staphylococcus aureus exacerbates inflammation and disrupts skin homeostasis.
- Environmental Triggers: Allergens, pollutants, and stress contribute to disease exacerbation. These interconnected factors underscore the importance of holistic models to study AD pathogenesis and evaluate therapeutic interventions.
Advantages of Non-Human Primate (NHP) Models for Atopic Dermatitis Research:
Advantages of NHP Models Compared to Mouse Models for Atopic Dermatitis Research:
Study design and clinical endpoints
Prisys Biotech's NHP AD model is meticulously designed to emulate human disease and provide actionable insights:
Study design:
Clinical endpoints:
1.Clinical Scoring: Erythema, scaling, pruritus, and lesion severity (adapted from the EASI scale).
2.Histopathological Analysis: Evaluation of epidermal hyperplasia, inflammatory cell infiltration, and mast cell activity.
3.Biomarker Quantification: Levels of serum IgE, IL-4, IL-13, and IFN-γ.
4.Behavioral Observations: Pruritus frequency and severity.
5.Skin Microbiome Analysis: Profiling of microbial communities.
6.Pulmonary Function Tests: For cases of co-induced asthma, pulmonary responses to acetylcholine (ACh) are assessed.
key result and figure legend
Related capabilities. This model is commonly combined with pharmacodynamics (PD) services, immunogenicity assessment, inhalation pharmacokinetics and lung function and CT imaging within an integrated NHP study.
Hot Tags: atopic dermatitis nhp model, research, study, monkey, gene therapy, NHP Asthma Dermatitis Model, Coagulation Hemostasis Nonhuman Primates, Pulmonary Artery Hypertension Nonhuman Primates Disease Model, Glaucoma Nonhuman Primates, Inflammatory Bowel Disease Nonhuman Primates Disease Model, Hemophilia A Nonhuman Primates
You Might Also Like
Send Inquiry



















